{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:23:28Z","timestamp":1778073808003,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,9]]},"DOI":"10.7759\/cureus.41604","type":"journal-article","created":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T21:01:01Z","timestamp":1688936461000},"source":"Crossref","is-referenced-by-count":2,"title":["A Rare Case of Olmesartan-Associated Enteropathy Successfully Managed With Steroid Taper"],"prefix":"10.7759","author":[{"given":"Angela","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Sturkie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Raff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2003.11927893","article-title":"Angiotensin II receptor blockers","volume":"16","author":"Barreras A","year":"2003","unstructured":"Barreras A, Gurk-Turner C. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent). 2003, 16:123-6. 10.1080\/08998280.2003.11927893","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-017-0087-5","article-title":"Management of hypertension using olmesartan alone or in combination","volume":"6","author":"Zhang X","year":"2017","unstructured":"Zhang X, Zhang H, Ma Y, Che W, Hamblin MR. Management of hypertension using olmesartan alone or in combination. Cardiol Ther. 2017, 6:13-32. 10.1007\/s40119-017-0087-5","journal-title":"Cardiol Ther"},{"key":"ref3","unstructured":"Olmesartan. drug usage statistics, United States, 2013 - 2020. (2022). Accessed: June 20, 2023: https:\/\/clincalc.com\/DrugStats\/Drugs\/Olmesartan."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpge.2016.02.005","article-title":"Sprue-like enteropathy associated with olmesartan: a new kid on the enteropathy block","volume":"23","author":"Hujoel IA","year":"2016","unstructured":"Hujoel IA, Rubio-Tapia A. Sprue-like enteropathy associated with olmesartan: a new kid on the enteropathy block. GE Port J Gastroenterol. 2016, 23:61-5. 10.1016\/j.jpge.2016.02.005","journal-title":"GE Port J Gastroenterol"},{"key":"ref5","unstructured":"FDA drug safety communication. FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. (2019). Accessed: June 8, 2023: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-approves-label-changes-inclu...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.003","article-title":"Severe spruelike enteropathy associated with olmesartan","volume":"87","author":"Rubio-Tapia A","year":"2012","unstructured":"Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012, 87:732-8. 10.1016\/j.mayocp.2012.06.003","journal-title":"Mayo Clin Proc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i40.6928","article-title":"Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug","volume":"19","author":"Nielsen JA","year":"2013","unstructured":"Nielsen JA, Steephen A, Lewin M. Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug. World J Gastroenterol. 2013, 19:6928-30. 10.3748\/wjg.v19.i40.6928","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.531","article-title":"Olmesartan-induced enteropathy associated with cutaneous lesions","volume":"4","author":"Hammoudi N","year":"2016","unstructured":"Hammoudi N, Dior M, Giraud V, Coffin B. Olmesartan-induced enteropathy associated with cutaneous lesions. Clin Case Rep. 2016, 4:379-82. 10.1002\/ccr3.531","journal-title":"Clin Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-201212001-00043","article-title":"A case of olmesartan induced enteropathy","volume":"18","author":"deFonseka A","year":"2012","unstructured":"deFonseka A, Tuskey A, Moskaluk C. A case of olmesartan induced enteropathy. Inflamm Bowel Dis. 2012, 18:17-8. 10.1097\/00054725-201212001-00043","journal-title":"Inflamm Bowel Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12780","article-title":"Systematic review: sprue-like enteropathy associated with olmesartan","volume":"40","author":"Ianiro G","year":"2014","unstructured":"Ianiro G, Bibb\u00f2 S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014, 40:16-23. 10.1111\/apt.12780","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goz019","article-title":"Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review","volume":"7","author":"Kamal A","year":"2019","unstructured":"Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, Hutfless SM. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (Oxf). 2019, 7:162-7. 10.1093\/gastro\/goz019","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13413","article-title":"Immunopathogenesis of olmesartan-associated enteropathy","volume":"42","author":"Marietta EV","year":"2015","unstructured":"Marietta EV, Nadeau AM, Cartee AK, et al.. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015, 42:1303-14. 10.1111\/apt.13413","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.07.003","article-title":"Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA-6 and the Bax pathway","volume":"424","author":"Sun L","year":"2012","unstructured":"Sun L, Wang W, Xiao W, Liang H, Yang Y, Yang H. Angiotensin II induces apoptosis in intestinal epithelial cells through the AT2 receptor, GATA-6 and the Bax pathway. Biochem Biophys Res Commun. 2012, 424:663-8. 10.1016\/j.bbrc.2012.07.003","journal-title":"Biochem Biophys Res Commun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4166\/kjg.2022.007","article-title":"Olmesartan-associated enteropathy with acute kidney injury","volume":"79","author":"Kang MJ","year":"2022","unstructured":"Kang MJ, Min KH, Kim HW, et al.. Olmesartan-associated enteropathy with acute kidney injury. Korean J Gastroenterol. 2022, 79:130-4. 10.4166\/kjg.2022.007","journal-title":"Korean J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0204-RA","article-title":"Olmesartan-associated enteropathy: a review of clinical and histologic findings","volume":"139","author":"Choi EY","year":"2015","unstructured":"Choi EY, McKenna BJ. Olmesartan-associated enteropathy: a review of clinical and histologic findings. Arch Pathol Lab Med. 2015, 139:1242-7. 10.5858\/arpa.2015-0204-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.45","article-title":"Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma","volume":"108","author":"DeGaetani M","year":"2013","unstructured":"DeGaetani M, Tennyson CA, Lebwohl B, et al.. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013, 108:647-53. 10.1038\/ajg.2013.45","journal-title":"Am J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12937","article-title":"Olmesartan-associated enteropathy: results of a national survey","volume":"40","author":"Marthey L","year":"2014","unstructured":"Marthey L, Cadiot G, Seksik P, et al.. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014, 40:1103-9. 10.1111\/apt.12937","journal-title":"Aliment Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2015.15","article-title":"A case of severe sprue-like enteropathy associated with valsartan","volume":"2","author":"Herman ML","year":"2015","unstructured":"Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J. 2015, 2:92-4. 10.14309\/crj.2015.15","journal-title":"ACG Case Rep J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2017.002","article-title":"Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study","volume":"34","author":"You SC","year":"2019","unstructured":"You SC, Park H, Yoon D, Park S, Joung B, Park RW. Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study. Korean J Intern Med. 2019, 34:90-8. 10.3904\/kjim.2017.002","journal-title":"Korean J Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309690","article-title":"Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study","volume":"65","author":"Basson M","year":"2016","unstructured":"Basson M, Mezzarobba M, Weill A, Ricordeau P, Allemand H, Alla F, Carbonnel F. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut. 2016, 65:1664-9. 10.1136\/gutjnl-2015-309690","journal-title":"Gut"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/167282-a-rare-case-of-olmesartan-associated-enteropathy-successfully-managed-with-steroid-taper","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:04Z","timestamp":1707508984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/167282-a-rare-case-of-olmesartan-associated-enteropathy-successfully-managed-with-steroid-taper"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,9]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.41604","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,9]]}}}